Advances in the modulation of ROS and transdermal administration for anti-psoriatic nanotherapies
Jiangmei Xu1,2, Hao Chen3, Haisheng Qian4
1Department of Dermatovenerology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, People's Republic of China.
Abstract:
Reactive oxygen species (ROS) at supraphysiological concentration have a determinate role in contributing to immuno-metabolic disorders in the epithelial immune microenvironment (EIME) of psoriatic lesions. With an exclusive focus on the gene-oxidative stress environment interaction in the EIME, a comprehensive strategy based on ROS-regulating nanomedicines is greatly anticipated to become the mainstay of anti-psoriasis treatment. This potential therapeutic modality could inhibit the acceleration of psoriasis via remodeling the redox equilibrium and reshaping the EIME. Herein, we present a marked overview of the current progress in the pathomechanisms of psoriasis, with particular concerns on the potential pathogenic role of ROS, which significantly dysregulates redox metabolism of keratinocytes (KCs) and skin-resident or -infiltrating cells. Meanwhile, the emergence of versatile nanomaterial-guided evolution for transdermal drug delivery has been attractive for the percutaneous administration of antipsoriatic therapies in recent years. We emphasize the underlying molecular mechanism of ROS-based nanoreactors for improved therapeutic outcomes against psoriasis and summarize up-to-date progress relating to the advantages and limitations of nanotherapeutic application for transdermal administration, as well as update an insight into potential future directions for nanotherapies in ROS-related skin diseases.
Insights
Reactive oxygen species (ROS) drive psoriasis by disrupting the skin’s immune environment. ROS-regulating nanomedicines offer a promising strategy to restore redox balance and treat psoriasis effectively.
Area of Science:
- Dermatology and immunology
- Nanomedicine
- Oxidative stress research
Background:
- Supraphysiological reactive oxygen species (ROS) concentrations are implicated in immuno-metabolic disorders within the epithelial immune microenvironment (EIME) of psoriatic lesions.
- The interaction between oxidative stress and gene expression in the EIME is a key factor in psoriasis pathogenesis.
- Dysregulation of redox metabolism in keratinocytes and skin cells by ROS contributes significantly to psoriatic disease progression.
Purpose of the Study:
- To provide an overview of psoriasis pathomechanisms, focusing on the role of ROS.
- To highlight the potential of ROS-regulating nanomedicines as a therapeutic strategy for psoriasis.
- To discuss the application of nanomaterial-guided transdermal drug delivery for psoriasis treatment.
Main Methods:
- Review of current literature on psoriasis pathomechanisms and the role of ROS.
- Analysis of the molecular mechanisms of ROS-based nanoreactors in psoriasis therapy.
- Evaluation of the advantages and limitations of nanotherapeutic transdermal administration.
Main Results:
- ROS significantly dysregulates the redox metabolism of keratinocytes and skin-resident/infiltrating cells in psoriatic lesions.
- Nanomaterial-guided transdermal drug delivery presents an attractive approach for percutaneous antipsoriatic therapies.
- ROS-based nanoreactors show potential for improved therapeutic outcomes by modulating the EIME and redox equilibrium.
Conclusions:
- Comprehensive strategies based on ROS-regulating nanomedicines are anticipated to be a mainstay in anti-psoriasis treatment.
- Nanomedicines can inhibit psoriasis progression by remodeling redox balance and reshaping the EIME.
- Future directions for nanotherapies in ROS-related skin diseases warrant further investigation.
